Overview
Stimulant dependence, particularly involving cocaine and amphetamine, represents a significant public health challenge characterized by neurobiological alterations including neurotransmitter dysregulation and cerebral perfusion abnormalities 1.Diagnosis
Clinical history of stimulant use and withdrawal symptoms
Neuropsychiatric assessments for depression and cognitive deficits 1
Laboratory tests to rule out other conditions (e.g., thyroid function tests) 1Management
First-line treatments:
- Antidepressants to address neurotransmitter re-normalization, particularly targeting dopamine and serotonin pathways 1
Adjunctive treatments:
- Dopaminergic and serotonergic agonists (limited efficacy in unselected patients) 1
- Peripheral cocaine blockers (specific agents not detailed) 1Special Populations
Pregnancy: Limited evidence; management focuses on minimizing harm and psychiatric support 1
Pediatrics: Specific pharmacological treatments not extensively studied; behavioral interventions recommended 1
Elderly: Consideration of polypharmacy risks; tailored psychotherapeutic approaches advised 1
Comorbidities: Integrated management addressing both stimulant dependence and concurrent conditions 1Key Recommendations
Utilize antidepressants to target neurotransmitter imbalances in stimulant-dependent patients (Evidence: Moderate) 1
Consider peripheral cocaine blockers as adjunctive therapy, though efficacy varies (Evidence: Weak) 1
Tailor treatment approaches for special populations, emphasizing behavioral interventions and careful monitoring of comorbidities (Evidence: Expert opinion) 1References
1 McCance-Katz E, Sevarino K, Gottschalk PC, Kosten T. Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 1999. link